Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Actelion_Pharmaceuticals_Ltd.
|
| gptkbp:activities |
endothelin receptor antagonist
|
| gptkbp:approves |
gptkb:2013
gptkb:FDA |
| gptkbp:brand |
gptkb:Opsumit
|
| gptkbp:clinical_trial |
approximately 80%
|
| gptkbp:contraindication |
pregnancy
severe hepatic impairment |
| gptkbp:developed_by |
gptkb:Actelion_Pharmaceuticals
|
| gptkbp:dosage_form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Macitentan
|
| gptkbp:ingredients |
C27 H33 N5 O3 S
|
| gptkbp:is_atype_of |
C02 K X01
|
| gptkbp:is_used_for |
pulmonary arterial hypertension
|
| gptkbp:manager |
oral
|
| gptkbp:side_effect |
gptkb:fandom
headache nasal congestion liver function test abnormalities |